Survival of Trial-Like and Non–Trial-Like Patients With Immunotherapy in Advanced Hepatocellular Carcinoma in Real World: A Collaborative Multicenter Indian Study (IMHEP) Hepatocellular carcinoma (HCC ...
Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment ...
The guidelines include recommendations for first-, second-, and third-line therapy. The American Society of Clinical Oncology (ASCO) has updated its guidelines on the use of systemic therapy for ...
Cancer Burden in Bangladesh: Insights From National Institute of Cancer Research & Hospital, 2014-2020 Hepatocellular carcinoma (HCC) is a major cause of cancer mortality in sub-Saharan Africa, with ...
Adjuvant therapy for hepatocellular carcinoma after curative treatment: Several unanswered questions
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally and is the third leading cause of cancer-related deaths. The primary curative treatments for HCC are liver ...
Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally and is the third leading cause of cancer-related deaths. The primary curative treatments for HCC are liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results